InoTerm ASTONISH
| Efficacy, Safety and Tolerability of Nangibotide in Patients with Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study
| Clinical Trial
(NCT04055909)
(2018-004827-36) | INOTERM S.A
| Commercial: Industry |
MK1439A-028 | Phase 2b, Double Blinded, Multicentre, Randomized study to assess the effect on central nervous system (CNS) toxicity of switching from Atripla (Efavirenz, tenofovir, emtricatabine) to MK-1439A (Doravine, Tenofovir, lamivudine) in virologically supressed subjects | Clinical Trial
(NCT02652260)
(2015-003617-18) | Merck | Commercial: Industry |
SOLAR study | A Phase IIIb, Randomized, Multicenter, Active-controlled,Parallelgroup, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months from a Bictegravir/emtricitabine/tenofovir alfenamide Single Tablet Regimen in HIV-1 Infected Adults who are Virologically Suppressed | Clinical Trial
( NCT04542070)
(2020-002623-11)
| GSK | Commercial: Industry |
Discovery | Multi-centre, adaptive, randomised trial of the safety and efficacy of treatments of Covid-19 in hospitalised adults
| Clinical Trial | INSERM
| Non-commercial: Hospital
|
PrEP
| A Phase 3, Randomized, Double-blind study to evaluate the safety and efficacy of emtricitabin and tenofovir alfaenamide (F/AF) Fixed dose combination once daily for pre-exposure prophylaxis in men and transgender women who have sex with men and are at risk of HIV 1 infection
| Clinical trial
| Gilead
| Commercial: Industry
|
Sprint-Sari
| Short Period Incidence study of severe Acute Respiratory Infection
| Observational-non invasive
| University College Dublin
| N/A
|
Covid Immune response in ICU
| Characterising the immune response in Covid-19 infection: towards identifying prognostic indicators of disease severity
| Observational with radiology or blood tests
| | N/A |
Eurosida
| EuroSIDA Prospective Observational Cohort Study on Clinical and Virological Outcome of European Patients Infected With HIV
| Observational-non invasive
| Rigshospitalet - University of Copenhagen
| Non-commercial: Academic
|
EU-SolidAct/Bari-SolidAct
| European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial / Efficacy and Safety of baricitinib for the treatment of severe COVID-19
| Clinical trial
| Oslo University Hospital
| Non-commercial: Hospital
|